GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OSTO:VIVE) » Definitions » EV-to-EBITDA

Vivesto AB (OSTO:VIVE) EV-to-EBITDA : -1.06 (As of Apr. 27, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Vivesto AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vivesto AB's enterprise value is kr75.58 Mil. Vivesto AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was kr-71.33 Mil. Therefore, Vivesto AB's EV-to-EBITDA for today is -1.06.

The historical rank and industry rank for Vivesto AB's EV-to-EBITDA or its related term are showing as below:

OSTO:VIVE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -246.28   Med: -8.61   Max: 307.71
Current: -1.06

During the past 13 years, the highest EV-to-EBITDA of Vivesto AB was 307.71. The lowest was -246.28. And the median was -8.61.

OSTO:VIVE's EV-to-EBITDA is ranked worse than
100% of 707 companies
in the Drug Manufacturers industry
Industry Median: 14.03 vs OSTO:VIVE: -1.06

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-27), Vivesto AB's stock price is kr0.285. Vivesto AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was kr-0.240. Therefore, Vivesto AB's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Vivesto AB EV-to-EBITDA Historical Data

The historical data trend for Vivesto AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivesto AB EV-to-EBITDA Chart

Vivesto AB Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.81 -243.87 -11.17 -0.95 -1.99

Vivesto AB Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.95 -0.39 -0.66 -0.57 -1.99

Competitive Comparison of Vivesto AB's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivesto AB's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Vivesto AB's EV-to-EBITDA falls into.



Vivesto AB EV-to-EBITDA Calculation

Vivesto AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=75.584/-71.329
=-1.06

Vivesto AB's current Enterprise Value is kr75.58 Mil.
Vivesto AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-71.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vivesto AB  (OSTO:VIVE) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Vivesto AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.285/-0.240
=At Loss

Vivesto AB's share price for today is kr0.285.
Vivesto AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.240.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Vivesto AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Vivesto AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivesto AB (OSTO:VIVE) Business Description

Traded in Other Exchanges
Address
Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.